Pilot Study of Optune for Recurrent Atypical and Anaplastic Meningioma Initiated
A pilot study is underway to evaluate the effects of the Optune device on recurrent atypical and anaplastic meningioma, which currently lacks effective treatments.
Phase III
Memorial Sloan Kettering Cancer Center
Status
Initiated
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The initiation of this pilot study for Optune in recurrent atypical and anaplastic meningioma is significant as it addresses a critical gap in treatment options for this patient population. Positive outcomes could lead to FDA approval, enhancing NovoCure's market position and expanding treatment protocols in neuro-oncology.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results and any announcements regarding FDA interactions or potential approval timelines.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.